About
Novel therapeutics for rare anterior segment ophthalmic diseases
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
83
By Phase
NA: 4PHASE2: 1
By Status
COMPLETED: 3UNKNOWN: 1TERMINATED: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT04574115Lead Sponsor
Clinical Investigation of Omega Refractive Capsule, Model VI
NAUnknown
30 participants
Started: Feb 6, 2021 · Completed: Jun 30, 2024
NCT04574102Lead Sponsor
Clinical Investigation of Omega Refractive Capsule Model V With Use of an FDA Approved IOL
NACompleted
6 participants
Started: Dec 9, 2020 · Completed: Nov 15, 2021
NCT04081103Collaborator
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
PHASE2Terminated
35 participants
Started: Jun 30, 2020 · Completed: Feb 7, 2022
NCT04058314Lead Sponsor
Clinical Investigation of OMEGA Gemini Capsule, Model Gemini IV With an Approved Monofocal or Toric IOL
NACompleted
6 participants
Started: Feb 21, 2020 · Completed: Aug 28, 2020
NCT04059796Lead Sponsor
Comparison of Gemini III Rev 2 Implanted in Conjunction With an Approved IOL vs Eyes Implanted With an Approved IOL
NACompleted
6 participants
Started: Feb 21, 2020 · Completed: Aug 28, 2020
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...